BioSpace News Archive

Vafidemstat reduces aggression in the three psychiatric disorders studied Patients with Borderline Personality Disorder show a more relevant improvement The company will shortly start a Phase IIb trial in this indication

Plus Therapeutics, Inc. (Nasdaq: PSTV) today announced that the compensation committee of the Company’s board of directors approved an inducement grant of stock options to purchase a total of 40,000 shares of common stock to Dr. Gregory Stein with a grant date of June 29, 2020 and an exercise price equal to $2.11, the fair market value on the grant date and a total of an additional 40,000 shares of common stock to Andrew Sims with a grant date o

A new study by researchers at Hospital for Special Surgery in New York City reveals that symptomatic lower back pain resolved in 82% of patients after total hip arthroplasty and identifies which patients are more likely to have their back pain resolved.

40,000 of Beckman Coulter’s new Access SARS-CoV-2 IgG Antibody tests already received by New York City through Lenco Labs

InMode Ltd. (Nasdaq: INMD) (“InMode”), a leading global provider of innovative medical technologies, is pleased to announce that it has received clearance from the China National Medical Products Administration NMPA - (previously known as CFDA) for two proprietary InMode radiofrequency platforms - the InMode RF platform and the InMode

Synapse Medicine has announced that it has raised 8 million dollars , spearheaded by the MACSF, a leading insurance provider for healthcare professionals, and with the support of XAnge, BNP Paribas, BPI, and Nicolas Dessaigne, co-founder of Algolia. The purpose of this move is to continue the development of its leading-edge medica

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that, based on currently available information, it estimates that both reported and organic revenue 1 growth will be approximately 10% for the second quarter ended June 27, 2020 . The better-than-expected organic revenue growth was prim

The Restylane® brand today announced results of a first-of-its-kind phase IV, Kissability study for an injectable hyaluronic acid (HA) lip filler, evaluating not only subject satisfaction but, for the first time, partner satisfaction following treatment with Restylane® Kysse

Two flexible financing solutions make essential pet care more affordable in the wake of COVID-19

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that as a result of continued clinical progress, the Israel Innovation Authority (IIA) has extended its previously awarded development